4WM
ZNTL icon

49 Wealth Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

49 Wealth Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-66,401
Closed -$155K – 302
2026
Q1 		$155K Sell
66,401
-4,510
-6% -$11.6K 0.01% 191
2025
Q4 		$95.7K Buy
70,911
+42,719
+152% +$62.2K 0.01% 193
2025
Q3 		$42.6K Buy
28,192
+6,646
+31% +$9.96K ﹤0.01% 194
2025
Q2 		$25K Sell
21,546
-23,967
-53% -$31.6K ﹤0.01% 176
2025
Q1 		$72.4K Buy
45,513
+18,874
+71% +$40.7K 0.01% 181
2024
Q4 		$80.7K Buy
26,639
+4,081
+18% +$13.4K 0.01% 166
2024
Q3 		$83K Buy
22,558
+10,145
+82% +$36.9K 0.01% 172
2024
Q2 		$52K Buy
12,413
+1,751
+16% +$19.6K 0.01% 152
2024
Q1 		$172K Buy
+10,662
New +$147K 0.04% 120

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

49 Wealth Management's ZNTL Position: Q2 2026 in Review

49 Wealth Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2026, closing a stake of 66,401 shares — an estimated $155K sold.

49 Wealth Management first reported a position in ZNTL in Q1 2024 and held it in 9 quarters. The position peaked at $172K in Q1 2024. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • 49 Wealth Management reported no remaining Zentalis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • 49 Wealth Management sold 66,401 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $155K.
  • 49 Wealth Management first reported a position in Zentalis Pharmaceuticals in Q1 2024 and held it in 9 quarters.
  • 49 Wealth Management's Zentalis Pharmaceuticals position peaked at $172K in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on 49 Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.